Evidence map›Paper›PMID 34882866›Full record

ArticleProtein science : a publication of the Protein Society2022

Characterization of protein-ligand binding interactions of enoyl-ACP reductase (FabI) by native MS reveals allosteric effects of coenzymes and the inhibitor triclosan.

P Matthew Joyner, Denise P Tran, Muhammad A Zenaidee, Joseph A Loo

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Protein science : a publication of the Protein Society, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 2 countries.

P Matthew JoynerNatural Science Division, Pepperdine University, Malibu, California, USA.ORCID 0000-0001-5135-9898
Denise P TranDepartment of Chemistry & Biochemistry, University of California-Los Angeles, Los Angeles, California, USA.
Muhammad A ZenaideeDepartment of Chemistry & Biochemistry, University of California-Los Angeles, Los Angeles, California, USA.
Joseph A LooDepartment of Chemistry & Biochemistry, University of California-Los Angeles, Los Angeles, California, USA.
University of California, Los Angeles · USPepperdine University · USThe University of Sydney · AU

Funding

UV Laser for Photodissociation-Mass Spectrometry of Proteins and Protein ComplexesR01GM103479 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOO, JOSEPH A · 2012 to 2021
$3.2M
High-Resolution Ion Mobility Mass SpectrometerS10OD018504 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LOO, JOSEPH A · 2014 to 2014
$915k
NIGMS NIH HHS R01 GM103479NIH HHS S10 OD018504
6 · The paper itself

Abstract

The enzyme enoyl-ACP reductase (also called FabI in bacteria) is an essential member of the fatty acid synthase II pathway in plants and bacteria. This enzyme is the target of the antibacterial drug triclosan and has been the subject of extensive studies for the past 20 years. Despite the large number of reports describing the biochemistry of this enzyme, there have been no studies that provided direct observation of the protein and its various ligands. Here we describe the use of native MS to characterize the protein-ligand interactions of FabI with its coenzymes NAD

Indexed as

TriclosanCoenzymesEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Fatty Acid Synthase, Type IILigandsCoenzymesEnoyl-(Acyl-Carrier-Protein) Reductase (NADH)Fatty Acid Synthase, Type IILigandsTriclosanallosterismantibacterialenoyl-ACP reductaseligand affinitynative MSprotein-ligand bindingprotein mass spectrometrytriclosan

Identifiers

PMID34882866
PMCPMC8862436
OpenAlexW4200053213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.